These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30664702)

  • 1. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial.
    Kim-Mitsuyama S; Soejima H; Yasuda O; Node K; Jinnouchi H; Yamamoto E; Sekigami T; Ogawa H; Matsui K
    Hypertens Res; 2019 Jun; 42(6):883-891. PubMed ID: 30664702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study.
    Ogawa H; Soejima H; Matsui K; Kim-Mitsuyama S; Yasuda O; Node K; Yamamuro M; Yamamoto E; Kataoka K; Jinnouchi H; Sekigami T;
    Eur J Prev Cardiol; 2016 Jun; 23(9):913-21. PubMed ID: 26324672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial.
    Kim-Mitsuyama S; Soejima H; Yasuda O; Node K; Jinnouchi H; Yamamoto E; Sekigami T; Ogawa H; Matsui K
    Sci Rep; 2019 Nov; 9(1):16589. PubMed ID: 31719604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study.
    Kim-Mitsuyama S; Ogawa H; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Hypertens Res; 2015 Mar; 38(3):199-207. PubMed ID: 25471234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Resistant hypertension and the risk of major adverse cardiac and cerebrovascular events in outpatients].
    Xia JH; Wang XY; Kang YY; Huang JF; Guo QH; Cheng YB; Li Y; Wang JG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2024 Aug; 52(8):884-891. PubMed ID: 39143779
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
    Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
    Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
    Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
    Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
    Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial.
    Kim-Mitsuyama S; Soejima H; Yasuda O; Node K; Jinnouchi H; Yamamoto E; Sekigami T; Ogawa H; Matsui K
    Sci Rep; 2018 Feb; 8(1):3150. PubMed ID: 29453374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.
    Hermida RC; Ayala DE; Fernández JR; Mojón A
    Chronobiol Int; 2013 Mar; 30(1-2):68-86. PubMed ID: 23181592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine.
    Hayashi K; Saruta T; Goto Y; Ishii M;
    Hypertens Res; 2010 Nov; 33(11):1211-20. PubMed ID: 20844543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
    Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.